October 04, 2023, Bengaluru, INDIA: Immuneel has been awarded ‘BIOPHARMA’S MOST PROMISING STARTUPS 2023’ at the ENDPOINTS 11 Awards event held on September 20, 2023, in Boston, USA.
The event annually honors the top 11 global biopharma startups after rigorous peer review research. This esteemed award not only underscores Immuneel’s significant contributions to transforming cancer care with innovative and affordable treatments but also positions the company as a global advocate for equitable access.
Immuneel extends its deep appreciation and gratitude to Endpoints News for this momentous award and is proud to represent India’s growing innovation-led biotech prowess at the international level. The vision of the founders was to put India on the CAR-T map, and this recognition goes a long way in acknowledging their efforts towards this goal.
As India’s first cell and gene therapy awardee on the global stage, Immuneel reaffirms its unwavering commitment to bringing breakthrough cell and gene therapies affordably to India and beyond.
Dr .Kush Parmar, co-founder of Immuneel, accepted the award.
The leadership team is led by seasoned medical and business professionals, with experience spanning across the medicine and biotech industry, our co-founders are – Kiran Mazumdar Shaw, Board Director and co-founder, Executive Chairperson, Biocon Limited, Siddhartha Mukherjee MD, DPhil, Cancer Physician, Columbia University, Scientific Co-founder, Vor Biopharmaand Kush M Parmar MD, PhD, Managing Partner, 5 AM Ventures and Dr. Arun Anand MD, Board Director & Chief Operating Officer, Immuneel Therapeutics.
